Most Ozempic, Wegovy Claims Survive MDL Dismissal Bid

By Matthew Santoni · August 18, 2025, 5:32 PM EDT

Eli Lilly & Co. and Novo Nordisk will have to face most of a multidistrict litigation accusing them of misleading consumers over the risks and benefits of popular weight loss drugs...

To view the full article, register now.

Documents

Case Information

Case Title

GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS (GLP-1 RAS) PRODUCTS LIABILITY LITIGATION

Case Number

2:24-md-03094

Court

Pennsylvania Eastern

Nature of Suit

P.I.: Health Care/Pharmaceutical Personal Injury Product Liability

Date Filed

February 05, 2024